Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|August 23, 2016
SCRS Announces Site Scholarships
Advertisement
Ellicott City, MD – SCRS announces Site Scholarships sponsored by Total Clinical Trial Management (TCTM). TCTM recognizes the pivotal role SCRS provides in enhancing site success and ensuring their sustainability. These site scholarships will be awarded to site partners identified by TCTM that are not already members of SCRS.
“SCRS has reached over 3,000 research sites and welcomes this opportunity to support more sites in achieving their fullest potential,” said Christine Pierre, President of SCRS. “TCTM has taken a position of being site-centric and by providing these scholarships they are continuing to demonstrate their commitment to being a strong site partner.”
“TCTM is an enthusiastic supporter of SCRS and their mission, and we believe the clinical research ecosystem will be enhanced by enabling the involvement and supporting the membership of more research sites in SCRS,” commented Tim Evans, Vice President, Business Development at TCTM.
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 3,000 research sites in 49 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit
About Total Clinical Trial Management
Total Clinical Trial Management (TCTM) is a boutique contract research organization based in Dallas, Texas. TCTM has a unique perspective on emphasizing the relationship with the clinical research site as a primary driver for successful clinical trial completion. Visit
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5